JP2010037255A - Agent for preventing or ameliorating visual dysfunction - Google Patents

Agent for preventing or ameliorating visual dysfunction Download PDF

Info

Publication number
JP2010037255A
JP2010037255A JP2008200849A JP2008200849A JP2010037255A JP 2010037255 A JP2010037255 A JP 2010037255A JP 2008200849 A JP2008200849 A JP 2008200849A JP 2008200849 A JP2008200849 A JP 2008200849A JP 2010037255 A JP2010037255 A JP 2010037255A
Authority
JP
Japan
Prior art keywords
extract
ginger
perilla
visual function
agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008200849A
Other languages
Japanese (ja)
Inventor
Yoshishiro Takahashi
美城 高橋
Hidehiko Kondo
秀彦 近藤
Kojiro Hashizume
浩二郎 橋爪
Takatoshi Murase
孝利 村瀬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kao Corp
Original Assignee
Kao Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kao Corp filed Critical Kao Corp
Priority to JP2008200849A priority Critical patent/JP2010037255A/en
Publication of JP2010037255A publication Critical patent/JP2010037255A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

<P>PROBLEM TO BE SOLVED: To provide an agent for the prevention and/or amelioration of visual dysfunction, having high safety and useful as a drug, quasi-drug, food, etc. <P>SOLUTION: The agent for the prevention and/or amelioration of visual dysfunction contains one or more kinds of plants selected from Caesalpinia sappan, Zingiber officinale and Perilla frutescens or its extract as an active component. <P>COPYRIGHT: (C)2010,JPO&INPIT

Description

本発明は、RDH12遺伝子発現促進剤、PEDF遺伝子発現促進剤及び視機能低下予防又は改善剤に関する。   The present invention relates to an RDH12 gene expression promoting agent, a PEDF gene expression promoting agent, and a visual function lowering preventing or improving agent.

パソコン、インターネット、携帯メール等の普及に伴い、画像表示端末(Visual displayterminal(VDT))作業を行う時間が増えるとともに、目の疲れやそれに伴う全身的な疲労(眼精疲労)が問題となっている。実際、約12,000の民営事業所を対象として厚生労働省が行った「平成15年技術革新と労働に関する実態調査」において、仕事でのVDT作業で身体的な疲労を自覚している労働者の91.6%が「目の疲れ・痛みがある」と回答したと報告されている(非特許文献1)。   With the spread of personal computers, the Internet, mobile mail, etc., the time required to work on the image display terminal (Visual display terminal (VDT)) increases, and fatigue of the eyes and associated fatigue (eye strain) become a problem. Yes. In fact, the “Ministry of Health, Labor and Welfare” conducted by the Ministry of Health, Labor and Welfare conducted in about 12,000 private establishments, and the workers who were aware of physical fatigue in VDT work at work. It is reported that 91.6% replied that they had “eye fatigue / pain” (Non-patent Document 1).

また、老視、白内障、緑内障、加齢性黄斑変性を始めとした加齢に伴う視機能低下や、糖尿病網膜症等の疾病に伴う視機能低下は、QOL(Quality of Life)を低下させる原因となることから、それらについても予防・改善が必要とされる。とりわけ、高齢化社会においては、加齢に伴う視機能低下は深刻な問題となるものと考えられる。   In addition, deterioration of visual function associated with aging, such as presbyopia, cataract, glaucoma, and age-related macular degeneration, and deterioration of visual function associated with diseases such as diabetic retinopathy are causes of lowering QOL (Quality of Life). Therefore, it is necessary to prevent and improve them. In particular, in an aging society, deterioration of visual function associated with aging is considered to be a serious problem.

これまでにも、疲れ目、加齢・疾病に伴う視機能低下を改善する試みがなされ、アントシアニン(特許文献1)、アスタキサンチン(特許文献2)、菊花(特許文献3)等が視機能改善作用を有することが明らかとされてきた。しかしながら、これらの成分については、その作用メカニズムも詳細には明らかになってはおらず、視機能低下予防・改善作用についても十分満足できるものとは言い難い。   So far, attempts have been made to improve visual function deterioration associated with fatigue, aging / disease, and anthocyanins (patent document 1), astaxanthin (patent document 2), chrysanthemum flower (patent document 3) and the like improve visual function. Has been shown to have. However, the action mechanism of these components has not been clarified in detail, and it is difficult to say that the effect of preventing or improving visual function deterioration is sufficiently satisfactory.

また、疲れ目、及び加齢・疾病に伴う視機能低下の主な原因の一つとして網膜機能低下が挙げられる。網膜機能とは、網膜に存在する光の受容細胞である「視細胞」が、光シグナルを電気シグナルに変換し中枢に伝達する機能であるが、視細胞に存在する光レセプター、ロドプシンの減少は網膜機能低下を引き起こす原因の一つで、ブルーベリーやカシスに含まれるアントシアニンについて知られている視機能低下予防・改善作用には、ロドプシン再合成の促進作用が関与しているとされている(非特許文献2)。   Moreover, retinal function deterioration is mentioned as one of the main causes of tired eyes and visual function deterioration accompanying aging / disease. Retinal function is the function of “photocells”, which are light-receiving cells in the retina, that convert light signals into electrical signals and transmit them to the center. One of the causes of retinal dysfunction, known to be the prevention and amelioration of visual function loss for anthocyanins contained in blueberries and cassis, is said to be associated with the promotion of rhodopsin resynthesis (non- Patent Document 2).

ロドプシンは、オプシンという7回膜貫通型タンパクと共同因子のレチナール(11-cis-retinal)より構成されており、視細胞の外節(retina outer segment)の円盤状の膜組織に存在している。光により、11-cis-retinalからall-trans-retinalへの異性化が生ずると、オプシンは構造変化を起こしトランスデューシン(Gタンパク質)の活性化を引き起こす。情報伝達系の活性化の結果、光シグナルは電気シグナルに変換され、視神経を介して中枢へと伝えられることになる。一つの視細胞が再び光を受容するためには、all-trans-retinalが、複数の酵素反応によって11-cis-retinalに変換され、ロドプシンが再合成される必要があることが分かっている。   Rhodopsin consists of a seven-transmembrane protein called opsin and a cofactor, retinal (11-cis-retinal), and is present in the disc-shaped membrane of the retina outer segment. . When isomerization from 11-cis-retinal to all-trans-retinal occurs by light, opsin undergoes a structural change and causes activation of transducin (G protein). As a result of the activation of the information transmission system, the light signal is converted into an electrical signal and transmitted to the center via the optic nerve. In order for one photoreceptor cell to receive light again, it has been found that all-trans-retinal is converted to 11-cis-retinal by multiple enzyme reactions and rhodopsin needs to be re-synthesized.

RDH12(retinol dehydrogenase 12)遺伝子は、11-cis-retinolから11-cis-retinal(先述のロドプシンを構成するレチナール)への変換を触媒する酵素をコードする遺伝子で、ロドプシン再合成における重要な遺伝子である。RDH12の遺伝的欠損は重度の視覚障害をきたすことからも、視機能維持にとって重要な役割を担っていると考えられている(非特許文献3)。又、マウスを用いた研究においてRDH12が網膜変性の抑制作用を執することが示されている(非特許文献4)。これらのことから、RDH12の発現増強、機能亢進は、視機能低下の予防・改善の良い手段となると考えられる。   The RDH12 (retinol dehydrogenase 12) gene encodes an enzyme that catalyzes the conversion of 11-cis-retinol to 11-cis-retinal (the retinal that constitutes rhodopsin described above), and is an important gene in rhodopsin resynthesis. is there. Since the genetic deficiency of RDH12 causes severe visual impairment, it is considered to play an important role in maintaining visual function (Non-patent Document 3). In addition, in studies using mice, it has been shown that RDH12 exerts an inhibitory action on retinal degeneration (Non-patent Document 4). From these facts, it is considered that RDH12 expression enhancement and function enhancement are good means for preventing and improving visual function deterioration.

一方、PEDF(pigment epithelium-derived factor)は、血管新生阻害作用や神経保護作用を有する分泌タンパク質として知られている。加齢や酸化ストレスによりPEDFの発現減少が起こること、糖尿病網膜症、加齢黄斑変性等の眼疾患においてPEDFのヒト硝子体における濃度は低値を示すことが報告されており(非特許文献5)、視機能低下、とりわけ、加齢、及び疾病に伴う視機能低下と関連していると考えられている。また、網膜色素変性症モデル動物においてPEDFを発現するウイルスベクターを眼内注射することにより、網膜の視細胞の細胞死が抑制されることが報告されている(非特許文献6)ことから、PEDFの発現増強、分泌促進は、視機能低下の予防・改善の良い手段となると考えられる。 On the other hand, PEDF (pigment epithelium-derived factor) is known as a secreted protein having an angiogenesis inhibitory action and a neuroprotective action. It has been reported that PEDF expression decreases in human vitreous in eye diseases such as diabetic retinopathy, age-related macular degeneration, etc., due to aging and oxidative stress causing decreased expression of PEDF (Non-patent Document 5). ), And is thought to be associated with decreased visual function, especially with age and disease. In addition, it has been reported that cell death of photoreceptor cells in the retina is suppressed by intraocular injection of a viral vector expressing PEDF in a retinitis pigmentosa model animal (Non-patent Document 6). Increased expression and promotion of secretion are considered to be good means for preventing and improving deterioration of visual function.

この様に、RDH12及びPEDFの発現亢進、及び機能亢進或いは分泌促進は、視機能低下の予防・改善に重要であると考えられるが、このような機能を有した視機能低下予防・改善のための食品素材はこれまでに全く知られていない。   Thus, although it is thought that the expression enhancement of RDH12 and PEDF, enhancement of function, or promotion of secretion are important for prevention / improvement of visual function deterioration, for the prevention / improvement of visual function deterioration having such a function. No food ingredients are ever known.

一方、スオウ(Caesalpinia sappan、マメ科ジャケツイバラ属)はインド原産、ヒマラヤ、タイ、東南アジアに分布する常緑低木であるが、その心材は、ブラジリンおよびその酸化体であるブラジレイン、α−フェランドレンやオシメン等を主成分とする精油、及びタンニンを含み、漢方では蘇木(ソボク)と呼ばれ、抗炎症、鎮痛、腹痛、月経不調、打撲傷等に用いられる。その他、心臓の収縮力増強、中枢神経抑制、抗菌作用が知られている(非特許文献7)。
また、ジンジャー(Zingiber officinale、ショウガ科ショウガ属)はインド原産の多年生草本であるが、その根茎は、辛味成分であるジンゲロール、ショウガオール及びジンゲロン、芳香成分であるジンギベレン、リナロール、シトラール及びシオネールを含み、世界中で香辛料及び民間薬として広く用いられている。特に、アジアでは生食や漬物用、又カレー粉の原料として用いられ、西洋とアラブ諸国では、乾燥品が調理用やパン・菓子等に用いられる。漢方では生姜(ショウキョウ)と呼ばれ、新陳代謝機能向上の効能があるとされ、嘔吐、腹痛、腰痛、食欲増進等に用いられる(非特許文献8)。
シソの葉は、漢方では蘇葉(ソヨウ)と呼ばれ、解熱作用や防腐作用があるとされ、発刊、解熱、鎮咳、鎮痛薬として、気管支炎や風邪などに用いられる(非特許文献8)。最近の研究では、シソの葉の含有成分であるフラボノイドのルテオリンが強い抗アレルギー作用を示されている(非特許文献9)。又、シソ(Perilla frutescens、シソ科シソ属)は、中国の中南部原産の1年生草本であるが、その葉はロズマリン酸、アントシアニン系のシソニン、及びマロニルシソニン等の成分を含み、アレルギー疾患に有用として健康食品としても利用される。
On the other hand, Suesu (Caesalpinia sappan) is an evergreen shrub native to India and distributed in the Himalayas, Thailand, and Southeast Asia. It contains essential oils and tannins, and is called soboku in Chinese medicine and is used for anti-inflammation, analgesia, abdominal pain, menstrual disorders, bruises and the like. In addition, heart contraction force enhancement, central nerve suppression, and antibacterial action are known (Non-patent Document 7).
Ginger (Zingiber officinale) is a perennial herb native to India, but its rhizome includes gingerol, gingerol and gingeron, which are pungent components, and gingivalen, linalool, citral, and cionaire, which are aromatic components. Widely used as a spice and folk medicine around the world. In particular, it is used for raw foods and pickles in Asia, as a raw material for curry powder, and in Western and Arab countries, dried products are used for cooking, bread and confectionery. It is called ginger in Chinese medicine and is said to have an effect of improving metabolic function, and is used for vomiting, abdominal pain, back pain, appetite enhancement, etc. (Non-patent Document 8).
Perilla leaves are called soba in Chinese medicine and are said to have antipyretic and antiseptic effects, and are used for bronchitis, colds, etc. as published, antipyretic, antitussive and analgesic drugs (Non-patent Document 8) . In recent studies, the flavonoid luteolin, which is a component of perilla leaves, has shown a strong antiallergic effect (Non-patent Document 9). Perilla frutescens (Perilla frutescens) is an annual herb native to the central and southern parts of China, but its leaves contain ingredients such as rosmarinic acid, anthocyanin-based shisonin, and malonylshisonin. It is also useful as a health food.

しかしながら、これまでスオウ、ジンジャー又はシソの視機能低下予防又は改善作用については全く知られていない。   However, until now, nothing has been known about the effect of preventing or improving the visual function of suou, ginger or perilla.

WO01/001798号パンフレットWO01 / 001798 pamphlet WO2002/094253号パンフレットWO2002 / 094253 pamphlet 特開平11−246455号公報JP 11-246455 A 厚生労働省大臣官房統計情報部:2003年技術革新と労働に関する実態調査.,厚生労働省,2004年Ministry of Health, Labor and Welfare Minister's Secretariat Statistics Information Department: 2003 Survey of actual conditions related to technological innovation and labor. , Ministry of Health, Labor and Welfare, 2004 Matsumoto, H., et al. J. Agric. Food Chem. 54, 578-582, 2006Matsumoto, H., et al. J. Agric. Food Chem. 54, 578-582, 2006 Janecke, A. R., et al., Nat. Genet., 36, 850-854, 2004Janecke, A. R., et al., Nat. Genet., 36, 850-854, 2004 Maeda,A., et al.,J. Biol. Chem., 281, 37697-37704, 2006Maeda, A., et al., J. Biol. Chem., 281, 37697-37704, 2006 Tombran-Tink, J., et al., J. Neurosci., 15, 4992-5003, 1995Tombran-Tink, J., et al., J. Neurosci., 15, 4992-5003, 1995 Miyazaki, M., et al., Gene Therapy, 10, 1503-1511, 2003Miyazaki, M., et al., Gene Therapy, 10, 1503-1511, 2003 原色漢薬と飲片図鑑,顔焜榮,南天書局,1982年Primary color herbal medicine and drinks picture book, Facial mask, Nanten Shobo, 1982 原色牧野和漢薬草大図鑑、三橋博、北隆館,2002年Primary Color Makino Wakuhan Herb Encyclopedia, Hiroshi Mitsuhashi, Hokuryukan, 2002 Makino, T., et al., Biol. Pharm. Bull., 24, 1206-1209, 2001Makino, T., et al., Biol. Pharm. Bull., 24, 1206-1209, 2001

本発明は、安全で有用な視機能低下予防又は改善剤を提供することに関する。   The present invention relates to providing a safe and useful agent for preventing or improving visual function deterioration.

本発明者らは、天然物素材を探索した結果、スオウ抽出物、ジンジャー抽出物及びシソ抽出物に優れたRDH12遺伝子発現促進作用があること、更にジンジャー抽出物にはPEDF遺伝子発現促進作用もあることを見出し、本発明を完成した。   As a result of searching for natural product materials, the present inventors have found that Suo extract, Ginger extract and Perilla extract have excellent RDH12 gene expression promoting action, and Ginger extract also has PEDF gene expression promoting action. As a result, the present invention has been completed.

すなわち本発明は、下記1)〜3)に係るものである。
1)スオウ、ジンジャー及びシソから選ばれる1種以上の植物又はその抽出物を有効成分とするRDH12遺伝子発現促進剤。
2)ジンジャーの植物又はその抽出物を有効成分とするPEDF遺伝子発現促進剤。
3)スオウ、ジンジャー及びシソから選ばれる1種以上の植物又はその抽出物を有効成分とする視機能低下予防又は改善剤。
That is, the present invention relates to the following 1) to 3).
1) An RDH12 gene expression promoter comprising as an active ingredient at least one plant selected from Suou, Ginger and Perilla or an extract thereof.
2) A PEDF gene expression promoter comprising a ginger plant or an extract thereof as an active ingredient.
3) An agent for preventing or improving visual function deterioration, comprising as an active ingredient at least one plant selected from Suou, Ginger and Perilla.

本発明のRDH12遺伝子発現促進剤、PEDF遺伝子発現促進剤、及び視機能低下予防又は改善剤は、優れたRDH12遺伝子及び/又はPEDF遺伝子発現促進作用を有し、かつ生薬由来のため安全性も高いので、視機能低下を予防又は改善するための医薬品、食品等として有効である。   The RDH12 gene expression promoting agent, PEDF gene expression promoting agent, and visual function lowering preventing or improving agent of the present invention have an excellent RDH12 gene and / or PEDF gene expression promoting action and are highly safe because they are derived from crude drugs. Therefore, it is effective as a medicine, food, etc. for preventing or improving the deterioration of visual function.

本発明に用いるスオウとは、マメ科(Leguminosae)のジャケツイバラ属スオウ(Caesalpinia sappan)を、ジンジャーとは、ショウガ科(Zingiberaceae)のショウガ属ジンジャー(Zingiber officinale)を、及びシソとは、シソ科(Lamiaceae)シソ属シソ(Perilla frutescens)を意味し、何れも漢方生薬の起源植物として知られている。
スオウ、ジンジャー又はシソの植物の使用部位としては、その植物の全草、地上部、心材、辺材、葉、樹皮、枝、根茎、根、花、果実、実又は種子等が挙げられる。
上記使用部位のうち、これらは漢方で使用されている部位を用いることが好ましく、具体的には、スオウであれば心材を用いることがより好ましく、ジンジャーであれば根茎を用いることがより好ましく、シソであれば葉を用いることがより好ましい。
上記使用部位は、単独で或いはこれらを混合してそのまま又は粉砕して用いることができる。
The suo used in the present invention is a leguminosae Caesalpinia sappan, a ginger is Zingiberaceae zingiber officinale, and a perilla is Lamiaceae ( Lamiaceae) Perilla frutescens, all known as the origin of herbal medicine.
Examples of the use site of the plant of Suou, Ginger or Perilla include whole plant, above-ground part, heartwood, sapwood, leaf, bark, branch, rhizome, root, flower, fruit, fruit or seed of the plant.
Among the above-mentioned use sites, it is preferable to use the sites used in Chinese medicine, specifically, it is more preferable to use heartwood if Suou, more preferable to use rhizome if Ginger, If it is perilla, it is more preferable to use a leaf.
The above-mentioned use site can be used alone or after being mixed and pulverized.

スオウ、ジンジャー又はシソの抽出物としては、前記の使用部位をそのまま或いは乾燥した後に適用な大きさに切断したり、粉砕加工したりしたものを抽出して得られる抽出エキスの他、さらに分離精製して得られる活性の高い画分(成分)が包含される。   As an extract of Suou, Ginger or Perilla, in addition to an extract obtained by extracting the above-mentioned used part as it is or after being dried and cut to an appropriate size or pulverized, it is further separated and purified The fraction (component) having high activity obtained in this manner is included.

上記植物の抽出手段としては、上記植物を低温(0〜4℃)、室温(5〜40℃)又は加温(40〜105℃)した状態で溶剤に含浸させるか又はソックスレー抽出器等の抽出器具を用いて行われる溶剤抽出法の他に、水蒸気蒸留等の蒸留法を用いて抽出する方法、炭酸ガスを超臨界状態にして行う超臨界抽出法、或いは圧搾して抽出物を得る圧搾法等が挙げられる。   As the plant extraction means, the plant is impregnated with a solvent in a state of low temperature (0 to 4 ° C.), room temperature (5 to 40 ° C.) or warm (40 to 105 ° C.), or extraction using a Soxhlet extractor or the like. In addition to the solvent extraction method performed using instruments, a method of extraction using a distillation method such as steam distillation, a supercritical extraction method in which carbon dioxide gas is brought into a supercritical state, or a pressing method to obtain an extract by pressing Etc.

溶剤抽出に用いられる抽出溶剤としては、極性溶剤、非極性溶剤のいずれをも使用することができ、これらを混合して用いることもできる。例えば、水;メタノール、エタノール、プロパノール、ブタノール等のアルコール類;エチレングリコール、プロピレングリコール、ブチレングリコール等の多価アルコール類;アセトン、メチルエチルケトン等のケトン類;酢酸メチル、酢酸エチル等のエステル類;テトラヒドロフラン、ジエチルエーテル等の鎖状及び環状エーテル類;ポリエチレングリコール等のポリエーテル類;ジクロロメタン、クロロホルム、四塩化炭素等のハロゲン化炭化水素類;ヘキサン、シクロヘキサン、石油エーテル等の炭化水素類;ベンゼン、トルエン等の芳香族炭化水素類;ピリジン類;超臨界二酸化炭素;油脂、ワックス、その他オイル等が挙げられ、これらは単独で又は2種以上を組み合わせて使用でき、溶剤を変えて繰り返し行うことも可能である。このうち、水、低級(炭素数1〜6)アルコール類又は水・低級(炭素数1〜6)アルコール類混液を用いるのが好ましく、当該低級アルコール類としては特にメタノール、エタノールが好ましい。   As the extraction solvent used for solvent extraction, either a polar solvent or a nonpolar solvent can be used, and these can also be mixed and used. For example, water; alcohols such as methanol, ethanol, propanol and butanol; polyhydric alcohols such as ethylene glycol, propylene glycol and butylene glycol; ketones such as acetone and methyl ethyl ketone; esters such as methyl acetate and ethyl acetate; tetrahydrofuran Linear and cyclic ethers such as diethyl ether; polyethers such as polyethylene glycol; halogenated hydrocarbons such as dichloromethane, chloroform and carbon tetrachloride; hydrocarbons such as hexane, cyclohexane and petroleum ether; benzene and toluene Aromatic hydrocarbons such as; pyridines; supercritical carbon dioxide; oils, waxes, other oils, and the like. These can be used alone or in combination of two or more, and can be repeated by changing the solvent. In . Among these, it is preferable to use water, a lower (C1-C6) alcohol, or a water / lower (C1-C6) alcohol mixed liquid, and methanol and ethanol are especially preferable as the lower alcohol.

抽出は、例えば上記植物1重量部に対して1〜50重量部の溶剤を用い、室温(5〜40℃)〜溶媒の沸点の範囲で1〜3時間から2〜3日間浸漬又は加熱還流するのが好ましい。   For extraction, for example, 1 to 50 parts by weight of a solvent is used per 1 part by weight of the plant, and the mixture is immersed or heated to reflux for 1 to 3 hours to 2 to 3 days in the range of room temperature (5 to 40 ° C.) to the boiling point of the solvent. Is preferred.

これらの抽出物としては、一例として、スオウの心材、ジンジャーの根茎又はシソの葉を20〜100容量%エタノール水溶液(エタノール:水=20〜100:80〜0(V/V))に室温(5〜40℃)、1〜10日間浸漬し、当該エタノール水溶液可溶成分を抽出して得られる抽出物が挙げられる。抽出温度としては、20〜40℃が好ましく、抽出期間としては5〜9日間が好ましく、抽出溶剤としては、20〜80容量%エタノール水溶液がより好ましく、40〜60容量%エタノール水溶液が更に好ましい。   As these extracts, as an example, Suo heartwood, ginger rhizome or perilla leaves are added to a 20-100 volume% ethanol aqueous solution (ethanol: water = 20-100: 80-0 (V / V)) at room temperature ( 5 to 40 ° C.) and an extract obtained by immersing for 1 to 10 days and extracting the ethanol aqueous solution-soluble component. The extraction temperature is preferably 20 to 40 ° C., the extraction period is preferably 5 to 9 days, the extraction solvent is more preferably 20 to 80% by volume ethanol aqueous solution, and further preferably 40 to 60% by volume ethanol aqueous solution.

抽出物の分離精製手段としては、例えば、活性炭処理、液液分配、カラムクロマトグラフィー、液体クロマトグラフィー、ゲル濾過、精密蒸留等を挙げることができる。   Examples of the means for separating and purifying the extract include activated carbon treatment, liquid-liquid distribution, column chromatography, liquid chromatography, gel filtration, and precision distillation.

本発明の抽出物は、斯くして得られる抽出液や画分をそのまま用いてもよく、適宜な溶媒で希釈した希釈液として用いてもよく、或いは濃縮エキスや乾燥粉末としたり、ペースト状に調製したものでもよい。
また、上記抽出物を凍結乾燥し、用時に、通常抽出に用いられる溶剤、例えば水、エタノール、水・エタノール混液等の溶剤で希釈して用いることもできる。また、リポソーム等のベシクルやマイクロカプセル等に内包させて用いることもできる。
The extract of the present invention may be used as it is, or may be used as a diluted solution diluted with an appropriate solvent, or as a concentrated extract or dry powder, or in a paste form. It may be prepared.
In addition, the above extract can be freeze-dried and diluted with a solvent usually used for extraction, for example, water, ethanol, water / ethanol mixed solution or the like. It can also be used by encapsulating in vesicles such as liposomes or microcapsules.

本発明の上記植物又はその抽出物は、後記実施例で示すとおり、RDH12遺伝子及び/又はPEDF遺伝子の発現増強作用を有し、これら各遺伝子の発現が増強されることによってRDH12タンパク質及び/又はPEDFタンパク質の発現亢進、及び機能亢進或いは分泌促進が起こり、疲れ目;網膜機能低下;老視、白内障、緑内障、加齢性黄斑変性等を始めとする加齢に伴う視機能の低下;白内障、緑内障、糖尿病網膜症、加齢性黄斑変性等疾病に伴う視機能の低下等の全般な視機能低下を予防及び/又は改善することができる(例えば、非特許文献3〜6参照。)。
ここで、視機能の低下の予防及び/又は改善とは、視機能の維持を包含するものである。
従って、上記植物又はその抽出物はこれを有効成分とするRDH12遺伝子発現促進剤、PEDF遺伝子発現促進剤並びに視機能低下予防及び/又は改善剤(以下、「視機能低下予防及び/又は改善剤等」ともいう)として使用することができ、また、視機能低下予防及び/又は改善剤等を製造するために使用することができる。当該視機能低下予防及び/又は改善剤等は、視機能低下を予防及び/又は改善するための食品、機能性食品、医薬部外品、医薬品等として使用可能である。そして、上記植物又はその抽出物は、視機能低下及び/又は改善のために用いる旨の表示を付した食品、例えば病者用食品、特定保健用食品等の特別用途食品として利用することができる。
The plant of the present invention or an extract thereof has an action of enhancing the expression of the RDH12 gene and / or PEDF gene, as shown in Examples below, and the expression of each of these genes is enhanced to enhance the RDH12 protein and / or PEDF. Increased protein expression and increased function or promotion of secretion, fatigue eyes; decreased retinal function; decreased visual function associated with aging, including presbyopia, cataract, glaucoma, age-related macular degeneration, etc .; cataract, glaucoma In addition, it is possible to prevent and / or improve general visual function decline such as diminished visual function associated with diseases such as diabetic retinopathy and age-related macular degeneration (see, for example, Non-Patent Documents 3 to 6).
Here, prevention and / or improvement of deterioration of visual function includes maintenance of visual function.
Therefore, the plant or the extract thereof is an RDH12 gene expression promoter, PEDF gene expression promoter, and visual function lowering prevention and / or improvement agent (hereinafter referred to as “visual function lowering prevention and / or improvement agent, etc. It can also be used for producing a visual function lowering prevention and / or improvement agent and the like. The visual function deterioration preventing and / or improving agent can be used as a food, functional food, quasi-drug, pharmaceutical, or the like for preventing and / or improving visual function deterioration. And the said plant or its extract can be utilized as food for special use, such as food with a label indicating that it is used for visual function deterioration and / or improvement, for example, food for the sick, food for specified health use, etc. .

本発明の視機能低下予防及び/又は改善剤等を医薬品として用いる場合の投与形態としては、例えば錠剤、カプセル剤、顆粒剤、散剤、シロップ剤等による経口投与又は注射剤、坐剤、吸入薬、経皮吸収剤、点眼薬、外用剤等による非経口投与が挙げられる。又、このような種々の剤型の医薬製剤を調製するには、本発明の上記植物又はその抽出物を単独で、又は他の薬学的に許容される賦形剤、結合剤、増量剤、崩壊剤、界面活性剤、滑沢剤、分散剤、緩衝剤、保存剤、嬌味剤、香料、被膜剤、担体、希釈剤等を適宜組み合わせて用いることができる。これらの投与形態のうち、好ましい形態は経口投与であり、経口投与用製剤として用いる場合の該製剤中の本発明の上記植物又はその抽出物の含有量は、一般的に0.01〜80質量%とするのが好ましく、0.5〜80質量%とするのがより好ましい。   Examples of the dosage form when the agent for preventing and / or improving visual function of the present invention is used as a pharmaceutical include oral administration by tablets, capsules, granules, powders, syrups, etc., or injections, suppositories, and inhalants. And parenteral administration using transdermal absorption agents, eye drops, external preparations and the like. In order to prepare pharmaceutical preparations of such various dosage forms, the above-mentioned plant of the present invention or an extract thereof can be used alone, or other pharmaceutically acceptable excipients, binders, bulking agents, Disintegrants, surfactants, lubricants, dispersants, buffers, preservatives, flavoring agents, fragrances, coating agents, carriers, diluents, and the like can be used in appropriate combinations. Among these dosage forms, the preferred form is oral administration, and when used as a preparation for oral administration, the content of the plant of the present invention or the extract thereof in the preparation is generally 0.01 to 80 mass. %, And more preferably 0.5 to 80% by mass.

本発明の視機能低下予防及び/又は改善剤等を食品として用いる場合の形態としては、パン類、ケーキ類、麺類、菓子類、ゼリー類、冷凍食品、アイスクリーム類、乳製品、飲料などの各種食品の他、上述した経口投与製剤と同様の形態(錠剤、カプセル剤、シロップ等)が挙げられる。
種々の形態の食品を調製するには、本発明の上記植物又はその抽出物を単独で、又は他の食品材料や、溶剤、軟化剤、油、乳化剤、防腐剤、香科、安定剤、着色剤、酸化防止剤、保湿剤、増粘剤等を適宜組み合わせて用いることができる。当該食品中の本発明の上記植物又はその抽出物の含有量は、0.001〜1.0質量%でありが好ましく、0.003〜0.5質量%とするのがより好ましく、0.005〜0.05%がさらに好ましい。
Examples of the case where the visual function deterioration preventing and / or improving agent of the present invention is used as food include breads, cakes, noodles, confectionery, jelly, frozen foods, ice creams, dairy products, and beverages. In addition to various foods, the same forms (tablets, capsules, syrups, etc.) as the above-mentioned oral preparations can be mentioned.
In order to prepare various forms of food, the above-mentioned plant of the present invention or an extract thereof is used alone, or other food materials, solvents, softeners, oils, emulsifiers, preservatives, fragrances, stabilizers, colorings. An agent, an antioxidant, a humectant, a thickener and the like can be used in appropriate combination. The content of the plant of the present invention or the extract thereof in the food is preferably 0.001 to 1.0% by mass, more preferably 0.003 to 0.5% by mass. 005 to 0.05% is more preferable.

本発明の視機能低下予防及び/又は改善剤等を医薬品又は食品として使用する場合、成人1人当たりの1日の投与又は摂取量は、年齢、体重、性別、投与方法などの種々の要因によって異なるが、経口投与の場合は上記植物又はその抽出物(固形分換算)として、本発明の上記植物又はその抽出物として、0.1〜5000mg、特に10〜2000mg、より好ましくは50〜1000mgの範囲を1日1回〜数回に分けて投与することが好ましい。   When the agent for preventing and / or improving visual function of the present invention is used as a medicine or food, the daily administration or intake per adult varies depending on various factors such as age, weight, sex, and administration method. However, in the case of oral administration, the plant or extract thereof (in terms of solid content) is 0.1 to 5000 mg, particularly 10 to 2000 mg, more preferably 50 to 1000 mg as the plant or extract thereof of the present invention. Is preferably administered once to several times a day.

製造例1:各抽出物
スオウ抽出物については、スオウ(Caesalpinia sappan)の心材乾燥粉砕物(生薬名:蘇木、産地:広西)200gを、10倍量(2リットル)の50%エタノール水溶液に室温(20〜30℃)で7日間浸漬し、不溶物を濾別後、減圧濃縮、凍結乾燥し抽出物を得た(固形分13.9g)。当該抽出物を50%エタノール水で1.0質量対容量(W/V)%に希釈し使用した。
ジンジャー抽出物については、ジンジャー(Zingiber officinale)の根茎乾燥粉砕物(商品名:ジンジャーパウダー)500gを、10倍量(5リットル)の50%エタノール水溶液に室温(20〜30℃)で7日間浸漬し、不溶物を濾別後、減圧濃縮、凍結乾燥し抽出物を得た(固形分21.3g)。当該抽出物を50%エタノール水で1.0質量対容量(W/V)%に希釈し使用した。
シソ抽出物については、シソ(Perilla frutescens var.acuta)の葉より抽出された食品用色素製剤(商品名:ダイヤモンドレッド;丸善製薬)を抽出物として用いた。当該色素製剤を50%エタノール水で1.0質量対容量(W/V)%に希釈し使用した。
Production Example 1: Each extract For Suo extract, 200 g of dry pulverized heartwood (Caesalpinia sappan) heartwood (name of crude drug: Sugi, place of origin: Guangxi) in 10 times amount (2 liters) of 50% ethanol aqueous solution It was immersed for 7 days at room temperature (20-30 ° C.), insoluble matter was filtered off, concentrated under reduced pressure, and lyophilized to obtain an extract (solid content 13.9 g). The extract was diluted with 50% ethanol water to 1.0 mass to volume (W / V)% and used.
As for the ginger extract, 500 g of dried ginger (Zingiber officinale) rhizome dried product (trade name: ginger powder) was immersed in 10 times (5 liters) of 50% ethanol aqueous solution at room temperature (20-30 ° C.) for 7 days. The insoluble material was filtered off, concentrated under reduced pressure, and lyophilized to obtain an extract (solid content: 21.3 g). The extract was diluted with 50% ethanol water to 1.0 mass to volume (W / V)% and used.
As for the perilla extract, a food color preparation (trade name: Diamond Red; Maruzen Pharmaceutical) extracted from perilla (Perilla frutescens var. Acuta) leaves was used as the extract. The dye preparation was diluted with 50% ethanol water to 1.0 mass to volume (W / V)% and used.

実施例1:Y79細胞におけるRDH12及びPEDF遺伝子発現亢進作用
24ウェルPoly-D-Lysineプレート(ベクトンディッキンソン社)に2.0×105 cells/wellのヒト網膜芽細胞腫由来細胞株Y79細胞懸濁液を播き、培養開始から1日目に培地を各試験サンプル、非働化処理した牛胎児血清(ThermoTrace社)及び100 units/ml penicillin、100μg/mLのstreptomycinを含むRPMI1640培地に交換した。
さらに、スオウ抽出物は0.001質量対容量(W/V)%、ジンジャー抽出物は0.01質量対容量(W/V)%、シソ抽出物は0.001質量対容量(W/V)%となるよう添加し、添加48時間後に細胞を回収し、核酸抽出試薬ISOGEN(日本ジーン)を用いてRNAを抽出した。total RNA125ngを用いて逆転写反応を行った。合成したcDNA(total RNA 6.25ng分)を用い、Real-time PCR法により、RDH12及びPEDFのmRNA発現量の定量を行った。
Example 1: RDH12 and PEDF gene expression enhancing action in Y79 cells Suspension of human retinoblastoma cell line Y79 cells at 2.0 × 10 5 cells / well in a 24-well Poly-D-Lysine plate (Becton Dickinson) On the first day from the start of culture, the medium was replaced with RPMI 1640 medium containing each test sample, inactivated fetal bovine serum (ThermoTrace), 100 units / ml penicillin, and 100 μg / mL streptomycin.
Furthermore, Suo extract is 0.001 mass to volume (W / V)%, Ginger extract is 0.01 mass to volume (W / V)%, Perilla extract is 0.001 mass to volume (W / V). %), 48 hours after the addition, the cells were collected, and RNA was extracted using a nucleic acid extraction reagent ISOGEN (Nippon Gene). Reverse transcription reaction was performed using 125 ng of total RNA. Using the synthesized cDNA (total RNA: 6.25 ng), mRNA expression levels of RDH12 and PEDF were quantified by Real-time PCR.

RDH12増幅用プライマー
5’側:AACTGCCAGACAGACCCCAG(配列番号1)
3’側:GCACCAGGGTTCCAGGACTT(配列番号2)
PEDF増幅用プライマー
5’側:ATTCCAACCATTCTGCACTGG(配列番号3)
3’側:TGCACAAAGTTGATGCCCTC(配列番号4)
36B4増幅用プライマー
5’側:CTGATCATCCAGCAGGTGTT(配列番号5)
3’側:CCAGGAAGGCCTTGACCTTT(配列番号6)
RDH12 amplification primer 5 'side: AACTGCCCAGACAGACCCCAG (SEQ ID NO: 1)
3 'side: GCACCAGGGTTCCAGGACTT (SEQ ID NO: 2)
PEDF amplification primer 5 'side: ATTCCAACCATTTCGCACTGG (SEQ ID NO: 3)
3 ′ side: TGCACAAAGTTGATGCCCTC (SEQ ID NO: 4)
Primer for amplification of 36B4 5 'side: CTGATCATCCAGCAGGGTTT (SEQ ID NO: 5)
3 'side: CCAGGAAGGCCTTGACCCTTT (SEQ ID NO: 6)

尚、解析はSYBR Green Master Mix及びABI PRISM7000 Seaquence Detectoin System(アプライドバイオジャパン社)を用いて行い、各遺伝子のmRNA発現量は、36B4(ribosomal protein, large, P0)遺伝子のmRNA発現量により補正した。又、遺伝子発現量は、溶媒コントロールにおける遺伝子発現量を1とした相対値で示した。
図1に示す様に、スオウ抽出物、ジンジャー抽出物及びシソ抽出物のいずれかの存在下で培養したY79細胞において、RDH12遺伝子発現量が増加した。又、図2に示す様に、ジンジャー抽出物の存在下で培養したY79細胞において、PEDF遺伝子発現量が増加した。このことから、スオウ、ジンジャー、シソは、視機能調節遺伝子発現を増加させ、視機能低下予防及び/又は改善剤として有効であることが分かる。
The analysis was performed using SYBR Green Master Mix and ABI PRISM7000 Seaquence Detectoin System (Applied Bio Japan), and the mRNA expression level of each gene was corrected by the mRNA expression level of 36B4 (ribosomal protein, large, P0) gene. . Moreover, the gene expression level was expressed as a relative value with the gene expression level in the solvent control being 1.
As shown in FIG. 1, the expression level of RDH12 gene was increased in Y79 cells cultured in the presence of any of Susu extract, Ginger extract and Perilla extract. Moreover, as shown in FIG. 2, the expression level of PEDF gene increased in Y79 cells cultured in the presence of ginger extract. From this, it can be seen that Suou, Ginger and Perilla increase visual function regulatory gene expression and are effective as a preventive and / or ameliorating agent for visual function deterioration.

実施例2
下記成分を用い、常法に従って1錠200mgの錠剤を製造した。
(組成) (%)
スオウ、ジンジャー、又はシソ抽出物 3.3
ヒドロキシプロピルセルロース 30
軽質無水ケイ酸 6.6
乳糖 16.7
結晶セルロース 16.7
タルク 16.7
ジアシルグリセロール 10
Example 2
One tablet of 200 mg was produced according to a conventional method using the following components.
(Composition) (%)
Suou, Ginger or Perilla extract 3.3
Hydroxypropyl cellulose 30
Light anhydrous silicic acid 6.6
Lactose 16.7
Crystalline cellulose 16.7
Talc 16.7
Diacylglycerol 10

実施例3
下記成分を用い、常法に従って1錠200mgの錠剤を製造した。
(組成) (%)
スオウ、ジンジャー、又はシソ抽出物 10
デンプン 65
ステアリン酸マグネシウム 5
乳糖 20
Example 3
One tablet of 200 mg was produced according to a conventional method using the following components.
(Composition) (%)
Suou, Ginger or Perilla extract 10
Starch 65
Magnesium stearate 5
Lactose 20

実施例4
下記の成分を混合後ゼラチンカプセルに充填し、1錠250mgの軟カプセル剤を得た。
(組成) (%)
スオウエキス 20
ジンジャーエキス 20
シソエキス 10
乳糖 25
結晶セルロース 25
Example 4
The following ingredients were mixed and then filled into a gelatin capsule to obtain a soft capsule of 250 mg per tablet.
(Composition) (%)
Suo extract 20
Ginger Extract 20
Perilla extract 10
Lactose 25
Crystalline cellulose 25

実施例5
200gのグラニュー糖を200mLの水に加熱溶解した後、200gのジンジャースライスを加えて15分間加熱した。濾過により獲られた抽出液200mLに、800mLの炭酸水を加えることにより、ジンジャー飲料を作製した。
Example 5
After 200 g of granulated sugar was dissolved in 200 mL of water by heating, 200 g of ginger slice was added and heated for 15 minutes. A ginger drink was prepared by adding 800 mL of carbonated water to 200 mL of the extract obtained by filtration.

実施例6
500gのシソ葉を1800mLの熱水に加え、10分間加熱した。濾過により得られた抽出液に、30gのクエン酸と800gのグラニュー糖を溶解しシソ濃縮飲料を作製した。
Example 6
500 g of perilla leaf was added to 1800 mL of hot water and heated for 10 minutes. 30 g of citric acid and 800 g of granulated sugar were dissolved in the extract obtained by filtration to prepare a perilla concentrated beverage.

実施例7
実施例5で作製したジンジャー飲料を用い、下記に示した様に1カップ50gのゼリーを作製した。
先ず、下記成分を混合し過熱により溶解した。
ジンジャー飲料 750mL
グラニュー糖 100g
ゼラチン 25g
溶解後、さらに下記成分を加え混合後、器に流し4℃で冷却してゼリーを作製した。
レモン果汁 75mL
ジンジャー飲料 500mL
Example 7
Using the ginger beverage prepared in Example 5, 1 cup 50 g of jelly was prepared as shown below.
First, the following components were mixed and dissolved by overheating.
Ginger drink 750mL
100g of granulated sugar
Gelatin 25g
After dissolution, the following components were further added and mixed, then poured into a vessel and cooled at 4 ° C. to prepare a jelly.
Lemon juice 75mL
500ml ginger drink

実施例8
実施例6で作製したシソ濃縮飲料を用い、下記に示した様に1カップ50gのゼリーを作製した。
先ず、下記成分を混合し過熱により溶解した。
シソ濃縮飲料 200mL
水 800mL
グラニュー糖 50g
ゼラチン 60g
溶解後、さらに下記成分を加え混合後、器に流し4℃で冷却してゼリーを作製した。
ショウガ汁 75mL
当該ショウガ汁は、ショウガをすった後絞ったものである。
Example 8
Using the perilla concentrated beverage prepared in Example 6, 1 cup of 50 g of jelly was prepared as shown below.
First, the following components were mixed and dissolved by overheating.
Perilla concentrated beverage 200mL
800mL water
50g of granulated sugar
60g gelatin
After dissolution, the following components were further added and mixed, then poured into a vessel and cooled at 4 ° C. to prepare a jelly.
Ginger juice 75mL
The ginger juice is squeezed after ginger is rinsed.

スオウ抽出物、ジンジャー抽出物又はシソ抽出物の存在下で培養したY79細胞におけるRDH12の遺伝子発現量を示す図である。It is a figure which shows the gene expression level of RDH12 in the Y79 cell cultured in the presence of a susu extract, a ginger extract, or a perilla extract. ジンジャー抽出物の存在下で培養したY79細胞におけるPEDFの遺伝子発現量を示す図である。It is a figure which shows the gene expression level of PEDF in the Y79 cell cultured in presence of the ginger extract.

Claims (3)

スオウ、ジンジャー及びシソから選ばれる1種以上の植物又はその抽出物を有効成分とするRDH12遺伝子発現促進剤。   An RDH12 gene expression promoter comprising as an active ingredient at least one plant selected from Suou, Ginger and Perilla or an extract thereof. ジンジャーの植物又はその抽出物を有効成分とするPEDF遺伝子発現促進剤。   A PEDF gene expression promoter comprising a ginger plant or an extract thereof as an active ingredient. スオウ、ジンジャー及びシソから選ばれる1種以上の植物又はその抽出物を有効成分とする視機能低下予防又は改善剤。   An agent for preventing or improving visual function deterioration comprising, as an active ingredient, at least one plant selected from Suou, Ginger and Perilla or an extract thereof.
JP2008200849A 2008-08-04 2008-08-04 Agent for preventing or ameliorating visual dysfunction Pending JP2010037255A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2008200849A JP2010037255A (en) 2008-08-04 2008-08-04 Agent for preventing or ameliorating visual dysfunction

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008200849A JP2010037255A (en) 2008-08-04 2008-08-04 Agent for preventing or ameliorating visual dysfunction

Publications (1)

Publication Number Publication Date
JP2010037255A true JP2010037255A (en) 2010-02-18

Family

ID=42010156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008200849A Pending JP2010037255A (en) 2008-08-04 2008-08-04 Agent for preventing or ameliorating visual dysfunction

Country Status (1)

Country Link
JP (1) JP2010037255A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010280621A (en) * 2009-06-05 2010-12-16 Maruzen Pharmaceut Co Ltd Antioxidant, anti-inflammatory agent, anti-aging agent, skin cosmetic, and food and drink
KR101185106B1 (en) * 2012-02-10 2012-09-21 한국과학기술연구원 Composition for descending intraocular pressure containing extractions of the lindera genus
JP2014197993A (en) * 2013-03-29 2014-10-23 小林製薬株式会社 Gelatin-containing oral composition
FR3115437A1 (en) * 2020-10-27 2022-04-29 Guillaume Cerutti Collagen and shiso drink formula

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028404A1 (en) * 2000-10-03 2002-04-11 Senju Pharmaceutical Co., Ltd. Eye drops
JP2002371001A (en) * 2001-06-18 2002-12-26 Nagase & Co Ltd Prophylactic or therapeutic agent for cataract
JP2004002237A (en) * 2002-05-31 2004-01-08 Noriko Yagi Anti-aging herb
JP2007028997A (en) * 2005-07-27 2007-02-08 Kanebo Seiyaku Kk Liquid food mixed with crude drug essence and use of the same
JP2008072998A (en) * 2006-09-22 2008-04-03 Sanei Gen Ffi Inc Pigment-containing food and drink, and method for stably coloring the food and drink

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028404A1 (en) * 2000-10-03 2002-04-11 Senju Pharmaceutical Co., Ltd. Eye drops
JP2002371001A (en) * 2001-06-18 2002-12-26 Nagase & Co Ltd Prophylactic or therapeutic agent for cataract
JP2004002237A (en) * 2002-05-31 2004-01-08 Noriko Yagi Anti-aging herb
JP2007028997A (en) * 2005-07-27 2007-02-08 Kanebo Seiyaku Kk Liquid food mixed with crude drug essence and use of the same
JP2008072998A (en) * 2006-09-22 2008-04-03 Sanei Gen Ffi Inc Pigment-containing food and drink, and method for stably coloring the food and drink

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010280621A (en) * 2009-06-05 2010-12-16 Maruzen Pharmaceut Co Ltd Antioxidant, anti-inflammatory agent, anti-aging agent, skin cosmetic, and food and drink
KR101185106B1 (en) * 2012-02-10 2012-09-21 한국과학기술연구원 Composition for descending intraocular pressure containing extractions of the lindera genus
JP2014197993A (en) * 2013-03-29 2014-10-23 小林製薬株式会社 Gelatin-containing oral composition
FR3115437A1 (en) * 2020-10-27 2022-04-29 Guillaume Cerutti Collagen and shiso drink formula

Similar Documents

Publication Publication Date Title
Venthodika et al. Bioactive compounds of Aegle marmelos L., medicinal values and its food applications: A critical review
Onkaramurthy et al. Anti-diabetic and anti-cataract effects of Chromolaena odorata Linn., in streptozotocin-induced diabetic rats
US11160840B2 (en) Composition for improvement of muscle function containing 3,5-dicaffeoylquinic acid or chrysanthemum extract
WO2014042261A1 (en) Sirtuin gene potentiator, and pharmaceutical product, cosmetic product, and food product using same
KR20200002260A (en) Composition for preventing and treating of obesity or metabolic disease comprising Elaeagnus umbellata extracts
JPWO2015046486A1 (en) Obesity suppressing composition
JP6045845B2 (en) GLP-1 secretion promoter
Nouman et al. Phytochemical profiling of curry (Murraya koenijii) leaves and its health benefits.
Jalili et al. An overview of therapeutic potentials of Taraxacum officinale (dandelion): A traditionally valuable herb with a reach historical background
JP2010037255A (en) Agent for preventing or ameliorating visual dysfunction
KR101794006B1 (en) Anti inflammatory comprising plant extract
KR102099147B1 (en) Composition for preventing, ameliorating or treating obesity comprising Heracleum moellendorffii root and Torilis japonica mixed extract as effective component
JP2013063956A (en) Glp-1 secretion promoter
KR101188581B1 (en) Composition comprising Cyperus rotundus methalnol extracts for preventing or treating Sepsis
KR101594979B1 (en) Compositions for treating or preventing obesity containing extract or fractions of Euphorbia supina Raf.
KR20190006286A (en) Composition for treating or preventing inflammatory disease or obesity comprising an extract of schisandra chinesis
KR101760163B1 (en) Composition for anti-obesity comprising extract of Sargassum serratifolium as an effective component
CN113116791A (en) Sirtuin 1 activator and skin cosmetic for activating sirtuin 1
JP2009249331A (en) Plant-originated agent for preventing or ameliorating hyperlipemia
KR102234225B1 (en) Pharmaceutical Composition Comprising Extracts of Eucommia ulmoides Oliver and Achyranthes japonica for Preventing or Treating Obesity
KR20190103665A (en) Food composition for improving or preventing obesity containing extract of saururus chinensis
KR20200000174A (en) Composition for prevention, improvement or treatment of liver fibrosis or cirrhosis including Allium senescens L. Extract
JP7301347B2 (en) Sirtuin 1 activator and skin cosmetic for sirtuin 1 activation
JP6534500B1 (en) Glycerol Release Promoter
KR20130082249A (en) Composition for preventing or improving the metabolic syndrome containing parthenocissus tricuspidata extract

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20110614

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130423

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130820